- Home
- VEON vs APLS Comparison
VEON vs APLS Comparison
Compare VEON & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VEON
- APLS
- Stock Information
- Founded
- VEON 1992
- APLS 2009
- Country
- VEON Netherlands
- APLS United States
- Employees
- VEON N/A
- APLS N/A
- Industry
- VEON Telecommunications Equipment
- APLS Biotechnology: Pharmaceutical Preparations
- Sector
- VEON Telecommunications
- APLS Health Care
- Exchange
- VEON Nasdaq
- APLS Nasdaq
- Market Cap
- VEON 3.2B
- APLS 3.6B
- IPO Year
- VEON 1996
- APLS 2017
- Fundamental
- Price
- VEON $45.47
- APLS $27.52
- Analyst Decision
- VEON Strong Buy
- APLS Buy
- Analyst Count
- VEON 1
- APLS 18
- Target Price
- VEON $48.00
- APLS $46.71
- AVG Volume (30 Days)
- VEON 115.7K
- APLS 1.4M
- Earning Date
- VEON 03-20-2025
- APLS 02-28-2025
- Dividend Yield
- VEON N/A
- APLS N/A
- EPS Growth
- VEON N/A
- APLS N/A
- EPS
- VEON N/A
- APLS N/A
- Revenue
- VEON $3,955,000,000.00
- APLS $715,216,000.00
- Revenue This Year
- VEON N/A
- APLS $97.25
- Revenue Next Year
- VEON N/A
- APLS $12.68
- P/E Ratio
- VEON $5.45
- APLS N/A
- Revenue Growth
- VEON 7.36
- APLS 162.10
- 52 Week Low
- VEON $22.17
- APLS $24.34
- 52 Week High
- VEON $48.39
- APLS $71.90
- Technical
- Relative Strength Index (RSI)
- VEON 58.30
- APLS 38.99
- Support Level
- VEON $44.31
- APLS $26.84
- Resistance Level
- VEON $47.50
- APLS $28.59
- Average True Range (ATR)
- VEON 1.42
- APLS 1.12
- MACD
- VEON 0.06
- APLS -0.03
- Stochastic Oscillator
- VEON 65.94
- APLS 18.09
About VEON VEON Ltd. ADS
VEON Ltd is a provider of mobile and fixed-line connectivity as well as digital services. Currently, the company offers services to customers in the following countries: Pakistan, Ukraine, Kazakhstan, Bangladesh, Uzbekistan, and Kyrgyzstan. The reportable segments currently consist of the following five segments: Pakistan, Ukraine, Kazakhstan, Bangladesh, and Uzbekistan. The company provides services under the Beeline, Kyivstar, Banglalink and Jazz brands.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.